Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 4/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26170494 | 0.88 | OPRL1 (0.43) | — | |
| SCHEMBL18074011 | 0.86 | PIK3CD (0.45) | PIK3CDHRH3CYP2D6SMN1; SMN2KDM4E | |
| SCHEMBL9976596 | 0.86 | PIK3CD (0.45) | PIK3CDHRH3CYP2D6SMN1; SMN2KDM4E | |
| SCHEMBL24792967 | 0.83 | PIK3CD (0.38) | PIK3CDHRH3SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL3419598 | 0.82 | PIK3CD (0.44) | PIK3CDHRH3CYP2D6SMN1; SMN2KDM4E | |
| SCHEMBL12385991 | 0.82 | SLC18A3 (0.38) | SMN1; SMN2SLC18A3 | |
| SCHEMBL12384237 | 0.82 | SLC18A3 (0.34) | SLC18A3 | |
| SCHEMBL12384250 | 0.82 | SLC18A3 (0.34) | PIK3CDSMN1; SMN2KDM4ESLC18A3 | |
| SCHEMBL23945597 | 0.82 | PIK3CD (0.41) | PIK3CDHRH3CYP2D6SMN1; SMN2KDM4E | |
| SCHEMBL26295620 | 0.81 | SMN1; SMN2 (0.53) | PIK3CDHRH3CYP2D6SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217947-A1 | Morpholinylquinazoline Compound, Pharmaceutical compositions thereof and Use Thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240025863-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| US-11787800-B2 | BRD9 degraders and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-8772301-B2 | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8202887-B2 | 2-(substituted-amino)-benzothiazole sulfonamide HIV protease inhibitors | JANSSEN R&D IRELAND (IE) | 2012-06-19 | — | — | US | disclosed |
| US-8168639-B2 | Heterotricyclic compounds as serotonergic and/or dopaminergic agents and uses thereof | ATIR HOLDING S.A. (LU) | 2012-05-01 | — | — | US | disclosed |
| US-8168639-B2 | Heterotricyclic compounds as serotonergic and/or dopaminergic agents and uses thereof | ATIR HOLDING S.A. (LU) | 2012-05-01 | — | — | US | disclosed |
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20100216807-A1 | HETEROCYCLIC COMPOUNDS AS SEROTONERGIC AND / OR DOPAMINERGIC AGENTS AND USES THEREOF | ATIR Holding S.A (LU) | 2010-08-26 | — | — | US | disclosed |
| US-20100216807-A1 | HETEROCYCLIC COMPOUNDS AS SEROTONERGIC AND / OR DOPAMINERGIC AGENTS AND USES THEREOF | ATIR Holding S.A (LU) | 2010-08-26 | — | — | US | disclosed |
| US-20090209583-A1 | 2-(SUBSTITUTED-AMINO)-BENZOTHIAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2009-08-20 | — | — | US | disclosed |
| US-20080249130-A1 | Gut microsomal triglyceride transport protein inhibitors | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209583-A1 | 2-(SUBSTITUTED-AMINO)-BENZOTHIAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS | SPINT2, PEPD, DNPEP | PIK3CD 2138/4885HRH3 2231/4885CYP2D6 1123/4885 |
| US-20240217947-A1 | Morpholinylquinazoline Compound, Pharmaceutical compositions thereof and Use Thereof | HDAC6, HDAC9, HDAC7 | PIK3CD 10/4885HRH3 1544/4885CYP2D6 1284/4885 |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | PIK3CD 1248/4885HRH3 4228/4885CYP2D6 1170/4885 |
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | GRM5, GRM2, GRM1 | PIK3CD 2008/4885HRH3 1089/4885CYP2D6 3733/4885 |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | PIK3CD 1678/4885HRH3 3548/4885CYP2D6 2910/4885 |
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | PIK3CD 1598/4885HRH3 2014/4885CYP2D6 3897/4885 |
| US-20080249130-A1 | Gut microsomal triglyceride transport protein inhibitors | MTTP, CETP, FABP2 | PIK3CD 2547/4885HRH3 4041/4885CYP2D6 150/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | PIK3CD 321/4885HRH3 3631/4885CYP2D6 3599/4885 |
| US-20240025863-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | SOS1, SOS2, SOST | PIK3CD 3134/4885HRH3 4280/4885CYP2D6 3051/4885 |
| US-20100216807-A1 | HETEROCYCLIC COMPOUNDS AS SEROTONERGIC AND / OR DOPAMINERGIC AGENTS AND USES THEREOF | HTR1A, HTR1B, HTR1D | PIK3CD 1906/4885HRH3 241/4885CYP2D6 201/4885 |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | PIK3CD 1598/4885HRH3 2014/4885CYP2D6 3897/4885 |
| US-11787800-B2 | BRD9 degraders and uses thereof | BRD9, BRWD1, BRD2 | PIK3CD 1944/4885HRH3 1813/4885CYP2D6 3138/4885 |
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | PIK3CD 2008/4885HRH3 1089/4885CYP2D6 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.